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COMMENTARY
Resistance to Chloroquine Unhinges Vivax Malaria Therapeutics†
J. Kevin Baird*
Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, and Centre for Tropical Medicine, Nuffield Department of
Clinical Medicine, University of Oxford, Oxford, United Kingdom
After 6 decades during which it was almost completely ne-
glected, malaria workers have begun to acknowledge that vivax
malaria poses a serious threat to human health. Nearly 3 bil-
lion people live at risk of the infection, and 100 to 400 million
suffer clinical attacks each year (21, 23). Recent studies chal-
lenge the notion of Plasmodium vivax as a benign infection. A
spectrum of severe disease syndromes historically considered
the reserve of Plasmodium falciparum have been demonstrated
in vivax malaria (4, 20, 25, 28, 31). Realization of the threat
posed by this parasite, along with acknowledgment of the need
to eliminate all of the malarias (19), draws attention to several
important problems in the chemotherapeutic management of
vivax malaria.
The treatment of P. vivax requires a blood schizontocide
against the acute attack and a hypnozoitocide against the dor-
mant forms in the liver that are responsible for relapse. Over
the past 60 years, chloroquine and primaquine have been the
companion therapies of choice for radical cure of vivax ma-
laria. Resistance to chloroquine by the asexual blood stages of
P. vivax emerged on the Indonesian archipelago and is now
spreading through Southeast Asia (5). In 2009, the Ministry of
Health of Indonesia abandoned chloroquine as the blood schi-
zontocide component of radical cure and adopted artemisinin-
combined therapy (ACT) for use with primaquine (22). This
commentary explains how that decision, regardless of where
made, comes with no assurance of the safety or efficacy of
primaquine against relapse.
WARTIME CRISIS AND CLINICAL DEVELOPMENT
Understanding the difficulty in replacing chloroquine in rad-
ical cure requires examining the genesis of chloroquine and
primaquine as companion therapies in radical cure. In March
1942, Japanese forces occupied Java, thereby securing 95% of
the world supply of quinine. Allied forces checked the Japa-
nese advance at Guadalcanal in the Solomon Islands later that
year and suffered malaria attack rates of 1,700/1,000 person-
years despite chemoprophylaxis with quinacrine (also called
atebrine or mepacrine) (24). Troops evacuated from Guadal-
canal to nonmalarious zones were withdrawn from chemopro-
phylaxis and suffered vivax malaria attack rates of 3,700/1,000
man-years (16). This partly explains how in the Pacific theater
of World War II, 5 of 6 cases of malaria were caused by P.
vivax. The Allies deployed pamaquine, a then commercially
available 8-aminoquinoline known to be active against relapse
and to be relatively toxic (13). However, the plasma levels of
this drug increased 10-fold when administered with quinacrine
(Fig. 1), and serious toxicity problems occurred among Amer-
ican forces (9, 10). Lacking alternatives to quinacrine, the U.S.
Surgeon General ordered the withdrawal of pamaquine against
relapse (27) and precipitated a hastily executed antirelapse
drug discovery effort by the American government.
The Board for the Coordination of Malaria Studies under
the National Research Council oversaw a vast network of
clinics and laboratories managing 14,000 compounds from
synthesis to clinical trials (12, 29, 32). That board directed a
search for new antirelapse therapies that focused solely on
the 8-aminoquinolines despite their relatively high toxicities
because these were the only compounds with known activity
against relapse. Replacing pamaquine was viewed as a high-
priority national security matter significantly impacting the
likelihood and speed of victory in the Pacific, and yet the
task would require 8 years. With screening in rats and mon-
keys for safety, 22 candidate 8-aminoquinolines advanced to
clinical trials conducted by Alf Alving and his colleagues at
the University of Chicago. Those trials commenced just as
the Second World War came to a close, and primaquine did
not emerge as the drug of choice until about 1950. Earlier,
in 1946, chloroquine had been identified as a first-line blood
schizontocide for vivax malaria (26). The trials of Alving and
colleagues nonetheless routinely applied quinine as the
companion therapy because their experimental work had
already been rigorously standardized to quinine therapy
against the blood stages in assessing the activities of 8-amino-
quinolines against relapse (1, 8, 11).
SYNERGY
Alving and his colleagues noticed an important potential
confounding factor and executed a clinical trial designed to
gauge its impact. In 1948 they wrote, “Quinine was adminis-
tered concurrently with the drugs [candidate 8-aminoquino-
lines against relapse]… the synergistic effect of quinine on
pamaquin (sic) may also extend to pamaquin analogs…” (3).
Today this statement would not be understood by most work-
ers in malaria chemotherapeutics. Quinine, like most other
blood schizontocides, given even at very high doses consistently
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and completely fails to prevent relapse (32). Convention seg-
regates the antiparasitic activity of blood schizontocides and
that of hypnozoitocides: one does not depend upon the other
in achieving the elimination of parasites from the respective
chemotherapeutic compartments. This commentary explores
how this may be a fundamentally flawed assumption and, later,
examines the implications with respect to replacing chloro-
quine for treatment of vivax malaria.
As early as the 1920s, at least one report described the first
8-aminoquinoline, pamaquine, failing against relapse when not
administered with quinine (30). The early clinical trials by Alv-
ing’s colleagues examined pamaquine against relapse and ob-
served the same phenomenon: pamaquine administered concur-
rently with quinine consistently achieved much higher cure rates
than the two drugs administered consecutively (7, 8, 15, 17).
Alving et al. (2) referred to these early experiments when
explaining the rationale for a clinical trial published in 1955:
“These experiments, however, cannot be considered defini-
tive… The possibility of potentiation of the action of 8-amino-
quinolines against tissue stages by concurrent administration
of quinine, therefore, still remains a matter of uncertainty.”
Their clinical trial, as designed, largely resolved that uncer-
tainty.
They randomized 57 Caucasian prisoners at the Illinois State
Penitentiary to 3 groups of 19 men each. The experimental
challenge followed an elaborate protocol for biting mosquitoes
that ensured roughly equal numbers of sporozoites of Chesson
strain P. vivax from New Guinea among treatment groups (14,
18). All men became parasitemic and febrile within 14 days.
One group received 0.6 g and 0.4 g chloroquine base on the
same day that primaquine commenced (15 mg base in six daily
divided doses over 14 days). The two other groups received
precisely the same dose of primaquine along with identical
doses of quinine (2 g quinine in six daily divided doses over 14
days). However, one group received the quinine and prima-
quine on the same days (concurrent therapy) and the other
received quinine first and, after a 2-day pause, primaquine
(consecutive therapy). Figure 2 illustrates the cumulative inci-
dence of recurrent parasitemia among all three groups with
follow-up of nonrelapsing subjects lasting 114 to 373 days
(mean 319 days) postpatency. The concurrent administration
of quinine and primaquine achieved good efficacy; only a single
recurrence appeared, at 31 days postpatency (and 17 days after
cessation of therapy). Consecutive dosing, however, almost
completely failed; 15 of 19 subjects had recurrent parasitemias
between 62 and 122 days postpatency. The chloroquine arm
had 5 recurrences between 58 and 198 days. Alving and col-
leagues concluded that good efficacy of primaquine against
relapse required the coadministration of quinine or chloro-
quine.
The superior efficacy of quinine to chloroquine with prima-
quine against relapse (see Fig. 2) hints at chemical class-spe-
cific synergistic effects. Alving and colleagues later corrected
this deficiency by increasing the daily dose of primaquine to 30
mg over 14 days (for the Chesson strain of P. vivax only) (6).
Chloroquine and primaquine thus became the companion
therapies of choice for vivax malaria, and drug discovery for
this infection lapsed into a 60-year quiescence.
REPLACING CHLOROQUINE-PRIMAQUINE
The erosion to collapse of chloroquine efficacy in Indo-
nesia and the spread of the problem into South and South-
east Asia, where the vast majority of vivax malaria occurs,
commands attention to the observations of Alving and col-
leagues (2). The strategy of replacing chloroquine on the
FIG. 1. Drug-drug interaction between pamaquine and quinacrine,
1942. These data are for a single human subject characterized as
typical of many others in the original confidential report (9). The boxes
indicate days of dosing of pamaquine (10 mg every 4 h), quinine (600
mg every 8 h), or quinacrine (100 mg every 8 h). The administration of
quinacrine but not of quinine caused a 10-fold elevation in plasma
concentrations of pamaquine.
FIG. 2. Relapse among 57 Caucasian subjects (19/group) in the
United States who were challenged with sporozoites of the Chesson
strain of P. vivax and randomized to three treatment arms represented
by each line in the graph, as follows: 14 days of 2 g quinine daily
followed by a 2-day pause and then 14 days of 15 mg primaquine daily
(dashed line); precisely the same quinine and primaquine therapies
except administered on the same days (solid line); and 1 g of chloro-
quine administered on the first of 14 days of 15 mg primaquine daily
(dotted line). Data are from a study by Alving et al. (2).
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basis of efficacy against the asexual blood stages alone re-
quires reassessment. The synergistic effect of quinine or
chloroquine upon primaquine efficacy documented by Alv-
ing cannot be assumed for any given new blood schizonto-
cide: the safety and efficacy of primaquine against relapse,
when combined with another drug for radical cure of vivax
malaria, must be established for each candidate blood schi-
zontocide or combination thereof. This imposes serious ob-
stacles to safe and effective radical cure.
The developers of chloroquine-primaquine had virtually un-
limited access to infected soldiers and, especially, domestic
prisoners for their experimental challenge trials. This was a key
advantage because assessing the efficacy of primaquine against
relapse requires long-term follow-up in the absence of risk of
reinfection. Unlike falciparum malaria, biological ambiguities
imposed by hypnozoites prohibit distinguishing therapeutic
failures from reinfections, i.e., genotypes mismatched between
primary and secondary parasitemias may originate from either
reinfection or relapse. While it may be possible to measure
likely reinfection rates among treated cohorts and estimate the
risk attributable to relapse, statistical certainty with this ap-
proach would likely require relatively vast sample sizes. Heav-
ily exposed populations returned to areas where the parasite is
not endemic could provide the required analytical leverage and
practicality, but such populations may be very rare. The most
practical solution, despite high costs and difficult ethical issues,
may be experimental challenge of human and nonhuman (us-
ing Plasmodium cynomolgi in Macaca mulatta) primate subjects
in areas where the parasite is not endemic. That difficult task is
compounded by the inability to culture this parasite in contin-
uous in vitro systems and, thus, the requirement of regular
access to patients with vivax malaria. This in turn requires
inspired international cooperation and trust with fair sharing
of biological materials and the intellectual property derived
from them.
Indonesia has lost chloroquine-primaquine for radical
cure, and other nations in South and Southeast Asia may
soon follow. The selection of new blood schizontocide com-
panions to primaquine in the absence of evidence demon-
strating the safety and efficacy of primaquine against relapse
could be a reckless course. The prudent course demands
clinical trials of new blood schizontocides combined with
primaquine that include credible estimates of efficacy
against relapse. As Alving, his colleagues, and sponsors did
successfully, we need only accept the difficulty and necessity
of this task.
CONCLUSIONS
The loss of chloroquine to resistance in vivax malaria impels
the selection of new companion drugs to primaquine for rad-
ical cure of this infection. If the hypnozoitocidal activity of
primaquine requires an appropriate companion drug, the effi-
cacy of primaquine against relapse must be reestablished with
each new blood schizontocide paired with it. This imposes
serious difficulties because such trials must be conducted in
either rare special populations or experimental challenge tri-
als. Countries like Indonesia, having neither therapeutic op-
tions nor evidence, must field a radical cure having no proven
clinical benefit. In the absence of deliberate action by donors
and sponsors to resolve this quandary, other nations in the
region and beyond will face the same predicament. Resistance
to chloroquine unhinges vivax malaria therapeutics.
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